ERBB2 and breast cancer: Interestingly, a substantial number (38%) of the analyzed BC cell lines showed weak expression of HER2, which therefore might serve as models for the recently discussed group of HER2-low TNBC patients that were shown to benefit from novel therapies with antibody–drug conjugates (Trastuzumab deruxtecan) [67].